Earnings call
Sun Pharmaceutical Industries Q2 FY26 earnings call
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The company has launched ILUMYA in 35 countries, with some launches occurring over the last 1 year, and expects those launches to gain commercial traction; it believes ILUMYA will continue to grow as an ex-U.S. franchise. Consolidated sales were INR144,052 million in the second quarter FY26, growing 8.6% compared with the second quarter of FY25; gross margin was 79.3%, EBITDA was INR45,271 million, up 14.9% over Q2 last year, and EBITDA margin was 31.3%, against 29.6% in Q2 FY25 and 31.1% in the first quarter FY26. Market share for the Hedgehog inhibitor in Europe is in excess of 60%. ILUMYA was commercialized in all major markets and was available across 35 markets. The company had consolidated net cash of $2.9 billion after its investment in the Checkpoint business acquisition and settling the GxMDL case.
The numbers management gave
Results
- Consolidated sales were INR144,052 million in the second quarter FY26, growing 8.6% compared with the second quarter of FY25; gross margin was 79.3%, EBITDA was INR45,271 million, up 14.9% over Q2 last year, and EBITDA margin was 31.3%, against 29.6% in Q2 FY25 and 31.1% in the first quarter FY26.
Show source
Q2 FY '26 sales were at INR144,052 million, record a growth of 8.6% vis-a-vis the second quarter of FY '25.
- Net profit after tax was INR31,180 million in Q2 FY26, up 2.6% over reported net profit in Q2 last year; EPS was INR13 per share and the effective tax rate was 24.7%, compared with 15.8% in Q2 FY25 and 24.3% in the first quarter FY26.
Show source
Net profit after tax for Q2 FY '26 was INR31,180 million, which is up by 2.6% over the reported net profit of Q2 last year.
- The company recorded a forex gain of INR4,305 million during the quarter, compared with a gain of INR1,281 million during the same period last year.
Show source
During the first quarter of FY '26, the ETR was at 24.3%. forex gain during the quarter was INR4,305 million compared to a gain of INR1,281 million during the same period last year.
- First-half sales were INR2,81,913 million, growing 9.3% over the first half last year; gross margin was 79.4%, EBITDA was INR88,287 million, up 17% over the first half last year, EBITDA margin was 31.2%, and adjusted net profit was INR61,141 million, up 4.1% over adjusted net profit in H1 last year.
Show source
For the first half, sales were at INR2,81,913 million, registering a growth of 9.3% over the first half last year.
- Global Innovative Medicines sales were USD313 million in Q2 FY26, up 16.4%.
Show source
In Q2, FY '26, our Global Innovative Medicines sales were up by 16.4% to reach USD313 million.
- India formulation sales were INR47,348 million in Q2 FY26, growing 11% over Q2 last year, and accounted for 32.9% of total consolidated sales for the quarter.
Show source
Coming to India business for Q2, the sales of formulation in India were INR47,348 million, recording a growth of 11% over Q2 last year.
Show 8 more statements
Results
- U.S. business declined 4.1% to $496 million for the quarter; growth in Innovative Medicines led by ILUMYA, CEQUA and ODOMZO was offset by lower generics sales due to additional competition for certain products and lower lenalidomide sales. The U.S. accounted for 30% of consolidated sales for the quarter.
Show source
Our overall U.S. business declined by 4.1% to $496 million for the quarter.
- Formulation revenues in Emerging Markets were $325 million, up 10.9% over Q2 last year, with underlying constant-currency growth of 8%; broad-based growth in Generic and Innovative Medicines was aided by favorable currency movement.
Show source
Our formulation revenues in Emerging Markets were $325 million, up by 10.9% over Q2 last year.
- Emerging Markets accounted for 19.7% of Sun Pharmaceutical Industries Limited’s total consolidated revenue in the second quarter; among larger markets in local currency terms, South Africa and Brazil did well.
Show source
Emerging Markets accounted for 19.7% of total consolidated revenue for the second quarter.
- Formulation revenues in Rest of the World were $234 million, up 17.7% over Q2 last year; growth came from both Generics and Innovative Medicines, and Rest of the World markets accounted for approximately 14.2% of consolidated revenue.
Show source
Formulation revenues in Rest of the World were $234 million up 17.7% over Q2 last year.
- Consolidated R&D investment was INR7,827 million in Q2 FY26, or 5.4% of sales; Innovative R&D accounted for 38% of total R&D spend and was approximately 10% of Global Innovative Medicine sales for the quarter.
Show source
Consolidated investments towards R&D for Q2 FY '26 stands at INR7,827 million or 5.4% of sales.
- ETR was 24.5% and is expected to hover around 25%, as carry-forward tax-loss benefits and benefits from its facilities in Assam and Sikkim are getting over and the tax rate will normalize.
Show source
Our ETR has gone up to 24.5% and we expect it to be hovering around 25%.
Money and capital
- The company had consolidated net cash of $2.9 billion after its investment in the Checkpoint business acquisition and settling the GxMDL case.
Show source
Balance sheet continues to be strong with a net cash of $2.9 billion at a consolidated level.
- Intangible assets amount to about $471 million.
Show source
Jayashree Satagopan: Yes, it is about $471 million.
What it expects ahead
What management expects
- The company has launched ILUMYA in 35 countries, with some launches occurring over the last 1 year, and expects those launches to gain commercial traction; it believes ILUMYA will continue to grow as an ex-U.S. franchise.
Show source
Kirti Ganorkar: No, what I said is like ILUMYA, we are launched in 35 countries.
- The company anticipates that access to LEQSELVI and overall product uptake will continue to improve.
Show source
We anticipate access will continue to improve as well as overall uptake of the product.
- The company remains on track to launch UNLOXCYT in the U.S. in the second half of FY26.
Show source
And we remain on track to launch UNLOXCYT in the U.S. in the second half of FY '26.
- The company is planning to file an ILUMYA psoriatic arthritis sBLA during the second half of FY26.
Show source
We are also planning to file ILUMYA psoriatic arthritis sBLA during second half of FY '26.
What it is building and selling
Demand and pricing
- Market share for the Hedgehog inhibitor in Europe is in excess of 60%.
Show source
But in Europe, I think, is in excess of 60% market share.
- The company has over a 50% share of the Hedgehog inhibitor market among dermatologists in the United States.
Show source
In dermatologists, we have over a 50% share in the United States.
Segments
- ILUMYA was commercialized in all major markets and was available across 35 markets.
Show source
Our largest brand, ILUMYA is now commercialized in all the major markets and is available across 35 markets.
- U.S. Innovative Medicine sales surpassed generics for the first time during the quarter.
Show source
U.S. sales of Innovative Medicine has surpassed generics for the first time during the quarter.
- The company launched three new generic products in the U.S. and launched LEQSELVI in the second quarter.
Show source
For the second quarter, we launched three new generic products in the U.S. We also launched LEQSELVI this quarter, and we've been pleased with our initial access and the response from health care providers and patients that they've had to the product.
- Semaglutide product will be a pen product.
Show source
Even the Semaglutide, which Kirti is talking about will be a pen product.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Kunal Dhamesha: The first one on the intangible assets, which seem to have moved sharply from the March '25 level, almost around USD 950 million plus. So I can see the $300 million intangibles which have moved from under development to other intangible head, but if you could provide a broader moving pieces here?
Answer, jayashree satagopan
Jayashree Satagopan: Thank you, Kunal, for your question. The increase in the intangible assets is also due to the Checkpoint intangible that has got added during the quarter. And we also had a milestone payment for ODOMZO.
Answer, jayashree satagopan
Jayashree Satagopan: Yes, it is about $471 million.
Question
Kunal Dhamesha: So then rest of the $500 million, what is driving that?
Answer, jayashree satagopan
Jayashree Satagopan: So we had Leqselvi related apart from Checkpoint, which is another larger piece, as you would know.
Answer, abhishek sharma
Abhishek Sharma: So Kunal, Leqselvi moved from intangibles under development into intangibles.
Question
Kunal Dhamesha: Okay. So that's another $300 million, and there should be ODOMZO?
Answer, abhishek sharma
Abhishek Sharma: No, then the rest are several small items. It's largely Checkpoint and Leqselvi. Kunal Dhamesha: Secondly, on the incremental specialty spend that we had suggested that we would be spending around $100 million in this year related to the launches of Leqselvi and Unloxcyt. So is it fair to assume that some of that has started in Q2? And should we see the run rate to be more similar in the quarter 3, quarter 4 or should we expect some acceleration deceleration? Any color would be helpful?
Answer, richard ascroft
Richard Ascroft: Yes. I'm happy to address that. So we did see a slight increase in Q2, and we would expect to see further increases in Q3, Q4 particularly as we launch Unloxcyt. Kunal Dhamesha: And lastly, on the Generics piece. The generic Revlimid seems to have kind of gone down even on a sequential basis? Is it a fair assumption? And would it be now a meaningful contributor in this quarter?
Question
Kunal Dhamesha: In quarter 2 versus quarter 1, the movement of lenalidomide?
Answer, abhishek sharma
Abhishek Sharma: Yes. Okay. So on lenalidomide, we have said that Y-o-Y, there is a drop. Q-o-Q, the number is flat.
Question
Neha Manpuria: Thanks for taking my question. We have two questions on the specialty business. On Leqselvi, when should we start seeing revenue contribution from improving payer coverage and payer access that you talked about? Would more meaningful revenue contribution from this be evident, let's say, in the later part of this fiscal or more so would you say in fiscal '27? What would be your assumption there?
Answer, richard ascroft
Richard Ascroft: We're already starting to see paid prescriptions through commercial channels, and we would expect that to continue to grow throughout the year.
Question
Neha Manpuria: Yes, that's right.
Answer, richard ascroft
Richard Ascroft: We do expect to see continued growth. As you shared, the IL-23 market continues to grow as does the overall psoriasis market. We continue to release new data on ILUMYA and sharpen our sales and marketing tactics, so we would expect to see continued growth.
Question
Neha Manpuria: And the last one I have is on R&D spend. If you look at R&D, we are obviously tracking below the guidance that we had revised down last quarter. How should we think about R&D spend for the full year? Do we expect to pick up going into second half or would it remain at the current 5.5% level that you see?
Answer, dilip shanghvi
Dilip Shanghvi: So Neha, I think we should come in the lower end of the guidance overall, that's what is our assessment today.
Question
Vishal Manchanda: I have a question on the balance sheet. If I look at the other current assets, it's almost doubled since , March '25 from INR2,500 crores to almost INR5,000 crores. Could you clarify on this? What led to this?
Answer, jayashree satagopan
Jayashree Satagopan: Yes. This is mainly on account of the GxMDL settlement, which has gone into an escrow account.
Question
Vishal Manchanda: Sorry, which settlement?
Answer, jayashree satagopan
Jayashree Satagopan: Last quarter, we had a settlement on the GxMDL case, and that amount has been deposited in an escrow account.
Question
Vishal Manchanda: And second one on cosibelimab. I wanted to understand whether it has been filed for European markets. And whether our competitors, Keytruda and Libtayo, do they have a European approval already?
Answer, dilip shanghvi
Dilip Shanghvi: Yes, we are in the process of compiling the dossier for Europe. Once it's filed, we will share the update with investors.
Show 20 more questions
Question
Vishal Manchanda: Sorry, Hedgehog inhibito r. Dilip Shanghvi: So I think it all depends on different geographies.
Answer, dilip shanghvi
Rick can update on the U.S. market share. But in Europe, I think, is in excess of 60% market share.
Answer, richard ascroft
Richard Ascroft: Yes. And it depends on the customer. In dermatologists, we have over a 50% share in the United States. Vishal Manchanda: And in the overall market, including the oncologist?
Answer, richard ascroft
Richard Ascroft: The oncologists are slightly less. I don't have the exact figure for the overall market at this time. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q2 FY26 Earnings Call Transcript 06:30 pm Nov 05, 2025 Vishal Manchanda: And would dermatologists be the primary prescriber here?
Question
Richard Ascroft:It's both.
Answer, kirti ganorkar
Kirti Ganorkar: Yes, India, I think what we have told you in our last call also, India will be ready for the launch in the first wave when the LOE happens on the patent expires.
Answer, richard ascroft
Richard Ascroft: For Canada, I don't believe we share that information.
Question
Harith Ahamed: And in the ROW segment, we've seen a very strong growth this quarter, constant currency terms around 17% to 18%. And in the last quarter, we had alluded to some onetime sales. So has that continued into the second quarter?
Answer, abhishek sharma
Abhishek Sharma: So before we answer the drivers for this one, there is no one-off in this quarter sales. For ROW, basically, the growth has been led by both Generics as well as Innovative Medicines. But there is no one- off.
Question
Harith Ahamed: A couple of months back, there was an announcement by the U.S. President on 100% tariffs on patent drug imports into the U.S. Well, there's no final policy that's been released yet, but is this a risk for our IM products given that we are manufacturing these products outside the U.S. And at the same time, we are manufacturing these in geographies where U.S. already has a trade deal and these trade deals cover pharma as well. So how should we look at this particular risk? Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +
Answer, richard ascroft
I mean, we don't have any additional tariffs that we're paying today. The original announcement has been put on pause, and we're still awaiting the outcome of the Section 232 investigation.
Answer, jayashree satagopan
Jayashree Satagopan: This is mainly Checkpoint acquisition... Bharat: Because this amounts to almost like INR390 million, whereas we have paid almost INR500 million for Checkpoint. So just was trying to understand that there was a big difference?
Answer, abhishek sharma
Abhishek Sharma: No, the Checkpoint consideration is not USD500 million, Bharat, it's less. It's what we disclosed was USD355 plus.
Answer, jayashree satagopan
Jayashree Satagopan: Yes. There is some amount of increase in the working capital, whi ch we believe will get normalized in this quarter. As I was also mentioning in the initial commentary, there has been a settlement that has happened towards GxMDL plus our brand acquisitions that have happened, which is the reason why the cash flow overall has come down compared to the 1st April '25.
Question
Shyam Srinivasan: So by the end of the fiscal, we expect this to be -- the generation to be in line at least with the growth in PBT. Let's assume?
Answer, jayashree satagopan
Jayashree Satagopan: Yes. I think the cash generat ion to clarify has been good. Working capital changes happened during the quarter, and this has happened during this quarter. Other than that, there have been 2 other items. One is the business acquisition. The other one is a settlement. So they should get normalized.
Question
Shyam Srinivasan: And just on the opening comments now, I think called out that the U.S. business formulation, we have now innovative higher than Generics. So obviously, you don't call it out, but of the $500 million U.S. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q2 FY26 Earnings Call Transcript 06:30 pm Nov 05, 2025 formulation, so I assume $250 million, $260 million is now innovative. That's a 70%, 80% of global in
Answer, richard ascroft
Richard Ascroft: Our strategy is to grow both our Innovative Medicines business as well a s our Generics business.
Question
Aalok Shanghvi: Yes. So there is very little forex impact and the growth was led by both the Generics and the Innovative Medicines, particularly by ILUMYA and ODOMZO.
Answer, kirti ganorkar
Kirti Ganorkar: No, I can tell you broadly, the GLP market is very exciting, and it will continue to grow, but very difficult to give any specific numbers and what it will grow in the future. What we can say, we want to participate in the market whenever the first opportunity is available.
Question
Kunal Dhamesha: And will we be there in both the dosage forms, injectable as well as oral? Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q2 FY26 Earnings Call Transcript 06:30 pm Nov 05, 2025 Kirti Ganorkar: I don't want to disclose that much but we will remain competitive, if others launch, we'll also launch along with them.
Answer, richard ascroft
Richard Ascroft: Yes. We have already launched Leqselvi, so that sales force is in place, and we do now have the sales force in place for Unloxcyt. So we will start to obviously see those expenses. Some of these expenses will continue to occur in '27 and beyond as we continue to support and grow these 2 very important products.
Question
Damayanti Kerai: So is it reasonable to assume that majority of the fixed costs will be covered within this $100 million budget, which you have put aside? And then going ahead, it will be more variable costs in line with how products gain market share? Will that be a logical assumption to take?
Answer, richard ascroft
Richard Ascroft: I think so. What I would say is that the sales force, obviously, that cost will continue. Our marketing expenses will continue. The patient support programs will continue. Some of the upfront marketing costs will not. Those are more onetime costs, but we'll continue to have the carrying cost of the people as well as our marketing and patient support programs.
Question
Damayanti Kerai: My second question is a clarification on Revlimid opportunity. So should we assume September was the last quarter when you had some meaningful sales coming from that product? And going ahead, there will be virtually no sales? Or how should we look at that?
Answer, richard ascroft
Richard Ascroft: We'll have a small amount of sales for the rest of the fiscal year.
Question
Vishal Manchanda: So just a clarification on Fibromun, is the Phase III and Phase II data on soft tissue sarcoma and glioblastoma. Is yet to come out? Or it's already there? Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q2 FY26 Earnings Call Transcript 06:30 pm Nov 05, 2025 Dilip Shanghvi: Yes.
Answer, dilip shanghvi
I think both the data are yet to come out. But this is also something which will be disclosed by Philogen, who is managing the studies.
Question
Vishal Manchanda: Okay. Any time lines like would this be announced this fiscal year or it will take longer?
Answer, dilip shanghvi
Dilip Shanghvi: I mean I don't want to announce on their behalf, but I'm not aware that there is any delay in the recruitment or conduct of the study.
Question
Vishal Manchanda: On the GLP-1 compound, GL0034. We have been kind of pushing this like a bit -- considering the competitive landscape, we are probably pushing it later, I think. We're not hurrying to develop this. Is there a reason to this o r how should...
Answer, dilip shanghvi
Dilip Shanghvi: No, I think we are quite excited with the early data that we're getting with patients, both for MASH as well as for diabetes. And we would be presenting this data shortly. But the Phase II study also, I think we disclosed that should be i n the press release we've given that should start shortly global Phase II. Vishal Manchanda: And are we doing this through the recombinant route or the synthetic route?
Answer, dilip shanghvi
Dilip Shanghvi: So as on today, I think the initial -- all the studies have been done w ith synthetic. But at some point of time, we might even consider switching over to recombinant.
Question
Neha Manpuria: Quickly on Cequa, I know that Restasis already has enough generic players, b ut there is anticipation that you should see some more competition there. Does that impact our ability to grow Cequa at all? If we do see additional competition in Restasis, what do you think could be the impact on Cequa given how well you've been doing in that product?
Answer, richard ascroft
Richard Ascroft: We continue to see good growth for Cequa, even as new competitors have come to the market. We believe it has a good value proposition for patients, and we put in the right programs to support patients as well. So even as new competitors have entered, we have continued to grow and would expect to continue to do so.
Question
Neha Manpuria: A new competition coming into Restasis does not impact pricing at all for Cequa. Would that be a fair assumption?
Answer, richard ascroft
Richard Ascroft: Not really. No. I think what currently is in place for Restasis, it will just be eroded by further Generics. As you know, they've been able to hold on to quite a bit of share, but the Generics will largely compete with Restasis and won't have a meaningful impact on the other brands within the category.
Question
Neha Manpuria: And second question, I know there's a lot of uncertainty on the tariff situation, but I think there was another new investigation under the Section 301 that was mentioned recently. Does that in any way impact ILUMYA, even though we don't sell ILUMYA, in Europe, its through the partner. Do you think that could be under consideration as a part of this investigation? Any views you have around that?
Answer, richard ascroft
Richard Ascroft: I don't think we have any views at this time. I think as we shared before, the tariff situation, as you know, is very fluid and uncertain. So it's hard for us to predict what the impact will be on our -- on either our Generics or Innovative Medicines portfolio at this time.
Question
Surya Narayan Patra: So can you elaborate a bit on your specialty in the non-U.S. market business, although it has already been indicated that brands of U.S. is likely to see newer markets and hence, growth. So any incremental initiative thought process about expansion, extension of these brands, if you can?
Answer, kirti ganorkar
Kirti Ganorkar: No, what I said is like ILUMYA, we are launched in 35 countries. And some of the countries, the launch has happened over a period of last 1 year. So this launch will also get picked up, and we see there will be good commercial traction. So ex-U.S., I believe that ILUMYA will be a strong franchise for us to continue to grow. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q2 FY26 Earnings Call Transcript 06:30 pm Nov 05, 2025 Surya Narayan Patra: And second question is about the Semaglutide entry in Canada, although we have filed for that.
Question
Whether we will be there in the first round of commercialization? Or how later that we would be even if our filing is relatively recent. So any time line about the commercialization of the product in the Canada?
Answer, richard ascroft
Richard Ascroft: Yes, we really don't have any further comments on that at this time.
Question
Anubhav Sahu: And for our Innovative molecule, let's say utreglutide, I mean could you mention which key indication we are looking at? I mean I understand obesity, anti -diabetes, one of them, but there are other indications also which we are looking at?
Answer, jayashree satagopan
Jayashree Satagopan: Yes. Our ETR has gone up to 24.5% and we expect it to be hovering around 25%. This is what we've been guiding. We used to get some benefits on account of carry forward tax losses as well as the benefits of having our facilities in Assam and Sikkim. Those are getting over and therefore, the tax rate will get normalized.
Question
Surya Narayan Patra: And just one more point about the GLP-1 opportunity. So how do we position ourselves whether our focus would be vial oriented to enter into the domestic market or it would be pen-oriented approach that we follow?
Answer, dilip shanghvi
Dilip Shanghvi: Those are -- I mean we have to remain competitive, and we need to have a product which can compete with the best product. Even the Semaglutide, which Kirti is talking about will be a pen product. So that's not an issue.
Questions about this call
- When was the Sun Pharmaceutical Industries Q2 FY26 earnings call transcript filed?
- Sun Pharmaceutical Industries filed the transcript with the exchange on 11 Nov 2025. This page is built from that transcript.
- What does this page list?
- 24 statements from the transcript across 5 topics, 18 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 30 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.